drugtest.co is for sale · Single buyer · No agency, no broker
drugtest.co is the exact-match domain for one of the largest evergreen commercial categories in the United States. What you are buying is a turnkey content-authority platform: the domain, ~110 medically-reviewed pages including a complete 50-state + DC State Laws / Legal Center, a modern Astro 5 codebase with best-in-class SEO and GEO infrastructure, three interactive widgets, and four pre-wired monetization rails ready for switch-on.
No inflated traffic or revenue claims. This is a transferable digital-asset package. The downloadable Buyer Diligence Pack summarizes everything an acquirer needs to evaluate the asset offline.
Walkthrough
A short walkthrough of drugtest.co — the exact-match domain, the 50-state + DC State Laws / Legal Center, the editorial inventory, the four-rail monetization scaffolding, and what changes hands at close.
Market
$2.62B
US drug-testing market sized in the $2.6B range and projected toward $4.1B at a ~5.89% CAGR over the standard analyst forecast horizon.
Grand View Research
Workplace
~6.5M
DOT-regulated safety-sensitive workers across FMCSA, FAA, FRA, FTA, PHMSA, USCG.
US DOT ODAPC
Lead value
$50–$400
Typical employer drug-testing lead value (per submission). HR-services CPL runs $420–$2,800.
Martal Group
AI search
+206%
Reported ChatGPT outbound referral traffic growth — and ~90% of citations come from URLs ranking outside Google's top 20.
Semrush
The thesis
In a regulated vertical worth several billion dollars annually, with a buyer-facing audience of millions of HR officers, parents, clinicians, and individuals, the highest-trafficked search term has its exact-match .co already built, sourced, medically reviewed, and monetization-ready. The work that compounds — domain, content, infrastructure — is finished. The work that scales — marketing, partnerships, lead-gen activation — is left to the operator who knows it best.
Market timing
Drug and alcohol testing is a recession-proof, year-round, federally-mandated category. It is one of the rare verticals where regulation expands the addressable market every cycle.
Regulatory tailwind
SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs were updated to add fentanyl and norfentanyl to the authorized urine panel (and fentanyl to oral fluid). Every employer in the DOT-regulated universe is updating its policies and training in response — driving fresh, recurring search volume.
Regulatory tailwind
DOT's rule authorizing oral-fluid as a urine alternative remains in a holding pattern while HHS-certified oral-fluid labs come online. When that landscape changes, every DOT employer will need to make a specimen-selection decision — and drugtest.co is positioned to be the reference they consult.
Compliance pressure
More than 308,000 drug-and-alcohol violations have been recorded in the FMCSA Clearinghouse since its launch, and roughly one in thirty registered CDL drivers sits in prohibited status. Recent monthly reports show employer query volumes in the high six figures; failure-to-query penalties average $10,278.
Behavioral signal
Quest Diagnostics' Drug Testing Index, analyzing ~10 million workplace tests, found a more than six-fold year-over-year increase in specimen tampering — and overall workforce positivity at 4.6% (combined), the highest level in two decades. Demand for reference-grade, non-gray-market content is structurally accelerating.
The flagship content moat
The single largest content cluster on the site and the asset's strongest commercial differentiator after the exact-match domain. ~60 pages of decision-useful, sourced legal reference content purpose-built for the audiences that actually spend money in this category: multi-state employers, HR teams, compliance leads, and the employment counsel who serve them.
The GEO opportunity
Classic SEO is collapsing on informational queries. AI-driven answers — ChatGPT, Perplexity, Gemini, Google's AI Overviews — are the new entry point for the audiences this site serves. drugtest.co was built GEO-first.
What's included
Everything below transfers to the buyer at close.
Domain
Content
Codebase
Monetization
| Group | Pages | Representative examples |
|---|---|---|
| Hubs | 8 | Home, Test Types, Panels, Detection Windows, Substances, Workplace, At-Home, State Laws |
| Test-type pages | 5 | Urine, Saliva, Hair, Blood, Breath |
| Panel pages | 4 | 5-panel, 10-panel, 4-panel, DOT 5-panel |
| Workplace pages | 4 | DOT vs non-DOT, building a program, MRO & confirmation, cannabis & state law |
| State Laws — per-state pages | 51 | All 50 states + DC, each ~2,000+ words with cannabis status, workplace testing rules, off-duty protection, MMJ accommodation, statute citations, employer & worker takeaways |
| State Laws — cross-cutting pages | 6 | Cannabis by state, off-duty conduct, MMJ protections, multi-state employer guide, federal overlay, voluntary DFWPs |
| At-home pages | 3 | How tests work, reading results, talking to a teen |
| Long-form guides | 4 | Detection windows, employer compliance overview, false positives, screening vs confirmation |
| Substance reference | 4 + programmatic | THC, cocaine, opioids, amphetamines (expandable from data layer) |
| Comparison pages | 2 | Urine vs hair, 5-panel vs 10-panel (programmatic pattern) |
| Glossary | ~25 terms | MRO, GC-MS, cutoff, immunoassay, EtG, oral fluid, chain of custody … |
| E-E-A-T & legal | 7 | About, Editorial Policy, Authors, Disclaimer, Privacy, Terms, Affiliate Disclosure |
Programmatic page types (substances, glossary terms, detection windows by substance, compare pages) are data-driven from typed datasets — adding new pages is a matter of editing TypeScript records and committing.
Why drugtest.co specifically
Most domains are bought as brand wrappers. drugtest.co is bought because the brand is the search query.
Google has de-weighted EMDs in classic ranking for low-quality sites, but the effect on brand recognition, direct navigation, AI-citation memorability, and email open rates is intact and arguably stronger than ever. In regulated verticals (health, legal, finance), dictionary-word EMDs routinely trade in the $5K–$50K+ range undeveloped. drugtest.co is undeveloped no longer — it ships with an authority site already built on top of it.
.co has graduated from "the cheap .com alternative" to a recognized premium global ccTLD — strong with startups, with global brands, and with B2B buyers. NameBio data tracked roughly $2.0M in reported .co domain sales in a single recent twelve-month period, with year-over-year dollar volume up more than 60%.
The drug-testing SERP is dominated by gray-market sites. They have all the traffic and almost none of the monetization optionality: serious advertisers, payment processors, occupational-health partners, MROs, and acquirers won't work with them. drugtest.co is built on the opposite premise — clinical, sourced, no "beat the test" content, ever — which makes it the only brand-safe surface in the category. That position is enforced editorially, structurally (build-time validation), and through medical review.
The information architecture deliberately serves five distinct audiences — employers/HR, parents, athletes, healthcare/recovery, and individuals — each with its own hub and its own monetization surface. A buyer picks the audience their commercial channels are strongest with and activates from there; the others continue to compound in the background.
| Audience | Why it's commercially relevant | Primary rail |
|---|---|---|
| Employers / HR / safety & compliance | ~6.5M DOT-regulated safety-sensitive workers; ~56% of US employers test | Highest commercial value (lead-gen, compliance SaaS) |
| Occupational-health clinics & lab networks | Quest Diagnostics analyses ~10M workplace tests/year; 20,000+ collection sites operate in the US | Affiliate, lead-gen, sponsorship |
| Parents & caregivers | At-home test market sized in the $745M range with growth projections approaching $1.33B over the standard analyst forecast horizon | Affiliate (FDA-cleared kits), newsletter |
| Healthcare, recovery, treatment | Clinical monitoring; SAMHSA helpline surfaced site-wide | Trust-driven, sponsorship-friendly |
| Individuals | Pre-employment, peace-of-mind queries — the largest informational segment | Display advertising at scale |
Monetization model
Every rail below is built, wired, and disclosed in the live codebase. None are active — activation is the buyer's first-week task and is documented in MONETIZATION_PLAYBOOK.md.
| Rail | Surface | Pricing model | Range | Note |
|---|---|---|---|---|
| Advertising | Display ad slots (in-content, sidebar, footer) | CPM / RPM | $5 – $30 RPM in compliance/health-adjacent content | Networks typically require 50–100k monthly sessions. |
| Affiliate | At-home test kits, labs/collectors, MRO services, compliance SaaS | 10–30% commission or $25–$200 per qualified lead | Scales with traffic | ProviderCompare + AffiliateCard render disclosures automatically. |
| Lead generation | LeadForm on /workplace/ and /find-a-test/ | Per-lead | $50 – $400 per submission | HR services CPL ranges $420–$2,800 (Martal). Highest-revenue rail. |
| Newsletter | NewsletterCTA, footer, article-end | Owned audience → sponsorships | Direct revenue at ~5K subscribers | Strategic compounding asset. |
Illustrative 18-month revenue sketch (mid-case)
| Month | Sessions / mo | Newsletter | Affiliate | Advertising | Lead-gen | Total / mo |
|---|---|---|---|---|---|---|
| M0–M3 | 1–8k | $0 | $0–$200 | $0 | $0 | $0–$200 |
| M4–M6 | 8–25k | $0 | $200–$1,000 | $0 | $500–$2,000 | $700–$3,000 |
| M7–M12 | 25–60k | $0–$300 | $1,000–$2,500 | $0 (sub-threshold) | $2,000–$6,000 | $3,000–$8,800 |
| M13–M18 | 60–120k | $200–$800 | $2,500–$6,000 | $1,200–$4,500 | $6,000–$15,000 | $9,900–$26,300 |
Assumes: weekly new-page cadence, two affiliate partnerships activated by M4, one lead-gen partner by M6, ad-network application at the 25k threshold, no paid acquisition. Sources for rail ranges in the monetization table. Treat as a planning artifact only.
Valuation
The list price is set below the additive replacement cost of the asset's four components and well below the lower-bound prices of comparable transactions.
| Component | What it would cost to recreate | Low | High |
|---|---|---|---|
| drugtest.co exact-match domain | Premium .co EMD in a regulated, multi-billion-dollar vertical. Compare: dictionary .co domains in health/legal/finance routinely sell in the $5K–$50K+ range undeveloped. | $5,000 | $15,000 |
| Core editorial content — ~46 pages, sourced & medically reviewed | ~35,000+ words of expert-toned, primary-sourced copy across hubs, test types, panels, workplace compliance, at-home, guides, and glossary. Equivalent freelance cost at $0.30–$0.60 per word for category-expert writing. | $10,000 | $21,000 |
| State Laws / Legal Center — 51 state pages + 6 cross-cutting topic pages | A defensible 100,000+ word content moat covering drug testing employment law for all 50 U.S. states + DC. Each state page is ~2,000+ words structured against primary statutes (cannabis status, off-duty protection, MMJ employee accommodation, voluntary DFWP, statute citations, employer & worker takeaways). High commercial intent for lead-gen, employment-counsel referral, and compliance-SaaS advertising. Replacement cost at category-expert legal-research rates: comfortably $40K–$80K. | $40,000 | $80,000 |
| Astro 5 + TypeScript codebase, design system, 3 React islands | Production-grade build: clean static HTML, design tokens, schema emitters, sitemap, RSS, llms.txt, Pagefind, OG generation, Keystatic CMS config, CI workflow. Equivalent agency build budget for a publication of this caliber. | $8,000 | $18,000 |
| Monetization scaffolding (4 rails) + handoff documentation | AdSlot, AffiliateCard, ProviderCompare, LeadForm, NewsletterCTA — all wired, disclosed, inert. State-laws section adds dedicated LeadForm placements with state-specific "interest" pre-population for higher-fidelity lead routing. README, DEPLOY, CONTENT_GUIDE, MONETIZATION_PLAYBOOK, HANDOFF (operator-grade). | $2,000 | $4,000 |
| Replacement cost — additive | $65,000 | $138,000 | |
| drugtest.co list price | $24,500 | ||
| Comparable | Detail | Price | Basis | Source |
|---|---|---|---|---|
| Empire Flippers — avg content-site sale | Average closed transaction across content portfolio | $325,000 | ~27× monthly profit | empireflippers.com |
| NameBio Top-100 domain sales | Average closing price; floor to make the top-100 list was $85K | $457,648 avg · $142,131 median | Domain-only | NamePros · NameBio |
| Premium dictionary .co in regulated verticals | Health, legal, finance EMDs — undeveloped | $5,000 – $50,000+ | Domain-only | ClickRank · Studio36 |
| Motion Invest "starter content" listings | Pre-revenue or low-traffic turnkey sites | $800 – $150,000 | Built, pre-revenue | thewebsiteflip.com |
| Two-letter .com (top reported deal) | Reference data point for premium domain ceilings | $4,700,000 | Domain-only | Joker Media |
| drugtest.co | Built, brand-safe, ~46 pages, premium EMD, four-rail monetization wiring, pre-revenue | $24,500 | Domain + content + infra + docs | This listing |
Comp sources: Empire Flippers state-of-market, NamePros / NameBio top-100, ClickRank EMD analysis, Motion Invest review, Joker Media.
Who this is for
This asset is priced and structured for a specific operator. If you recognize yourself below, the acquisition pays for itself unusually quickly.
Honest disclosures
The asset is sold "as-is". The list below is the asset's actual limitations — read it before you buy.
This is a platform listing, not a cash-flow listing. Pricing reflects that. A buyer expecting an already-trafficked, already-monetized site should be looking elsewhere.
Author and medical-reviewer profiles are intentional placeholders. The HANDOFF document specifies replacing them in the first week — keeping a real, named, AAMRO/MROCC-certified MRO as the medical reviewer is the most valuable trust signal on the site and should not be skipped.
Clinical and regulatory content drifts. The HANDOFF specifies an annual review of clinical/workplace pages, quarterly checks against new SAMHSA/DOT guidance, and monthly content additions to keep the site growing. None of this is optional if the trust position is to hold.
Components are wired, fixed-dimension (no CLS), and disclosed — but no live partners, no live advertisers, no live ESP, no live CRM webhook. Activating each rail is a documented step, but a step the buyer takes.
The /workplace/cannabis-and-state-law/ page is structured to be updateable, but the underlying state landscape moves quickly. The buyer should expect to revise this page at least twice a year.
The shift to AI assistants is a tailwind for sites with primary-source citations and clean schema — and a headwind for thin content. drugtest.co is built for the new regime, but the regime itself is still settling; treat any traffic forecast as illustrative.
Download
A polished, offline-readable PDF that mirrors this page in acquisition-memo form: asset overview, what's included, buyer fit, commercialization paths, build-vs-buy comparison, a suggested phased growth plan, the transfer checklist, a diligence checklist for the buyer, and honest risk notes. Share it with co-buyers, counsel, or your board.
Process
Open the secure Escrow.com checkout for drugtest.co and fund the transaction at list price. Escrow.com is the neutral, regulated payments service used for premium domain and website transactions worldwide.
Escrow.com confirms your payment has cleared and holds the funds in a regulated trust account. We are notified that the buyer is funded and the inspection period begins.
The drugtest.co domain is pushed to your registrar of choice, the source repository is transferred to your GitHub organization, and the Cloudflare Pages deploy is reassigned (or migrated to Netlify/Vercel — both are documented drop-in alternatives).
Inside Escrow.com, you verify that the domain, repository, and content are in your control. On your confirmation, Escrow.com releases the funds. The transfer is irrevocable on both sides.
Asynchronous access for clarifying questions and one optional follow-up call. After that, the documentation is the contract — and the codebase was deliberately written so it does not need us.
Acquisition FAQ
Everything that ships drugtest.co as it stands today: the drugtest.co domain (transferred to the buyer's registrar of choice), the full source repository (~110 production pages including the entire 50-state + DC State Laws / Legal Center, design system, 3 interactive React islands, schema emitters, sitemap, RSS, llms.txt, robots.txt, OG image generation), all editorial content with primary-source citations and statute citations for every state, the monetization scaffolding for four revenue rails (advertising, affiliate, lead-gen, newsletter), Keystatic CMS configuration, CI workflow, and the complete operator documentation set (README, DEPLOY, CONTENT_GUIDE, MONETIZATION_PLAYBOOK, HANDOFF). Author and reviewer profiles are placeholders to be replaced by the buyer with real, named team members.
The State Laws section (/state-laws/) is the single largest content cluster on the site — a sourced, decision-useful reference covering drug testing employment law for all 50 U.S. states + the District of Columbia, plus six cross-cutting topic pages (cannabis testing by state, off-duty cannabis protection by state, MMJ employee protection by state, multi-state employer compliance guide, federal overlay & preemption, voluntary Drug-Free Workplace Programs). It is ~60 pages of high-commercial-intent content targeting "[state] drug testing laws," "cannabis workplace testing," "MMJ employee accommodation," and "multi-state HR compliance" — the exact queries that employers, HR, and employment counsel run when they're about to spend money. No competitor in the drug-testing category has anything comparable. It is structurally hard to replicate (each page combines a structured data layer with state-specific narrative drafted against primary statutes) and is the asset's single largest commercial differentiator after the exact-match domain.
It is a content-authority foundation, not an operating business. The work that is hardest to replicate — the domain, the editorial content, the technical SEO/GEO infrastructure, the schema layer, the monetization wiring — is finished. The work that scales linearly with budget and time — marketing, distribution, partnerships, lead-gen activation — is intentionally left for the buyer, who will know their own commercial channels better than any prior owner. Pricing reflects this: this is a "platform" listing, not a "cash-flow" listing, and the price is set accordingly.
Yes. drugtest.co is an exact-match domain for the primary category query "drug test." The .co extension reads as a brand (not as a knock-off of .com), is recognized as a premium global ccTLD, and reduces the brand-name conflict surface that plagues .com look-alikes in this category. The domain is registered and current.
drugtest.co does not publish, host, or optimize for content that helps anyone defeat, evade, adulterate, or cheat a drug test. That stance is enforced editorially, structurally (a build-time validate-sources check), and through medical review. The reason it matters to a buyer: the entire category online is dominated by gray-market "how to pass" sites, which are unmonetizable by reputable advertisers, blocked by most payment processors, and unattractive to serious lead-gen partners (occupational-health clinics, MROs, labs, compliance SaaS). The brand-safe position is the asset's single largest commercial differentiator.
Yes, under a short mutual NDA. We will share read-only repository access and a 30-minute walkthrough call covering the content model, monetization wiring, and deployment process. The repository is small, documented, and reviewable in a single sitting.
A typical handoff takes 5–10 business days inside the Escrow.com transaction: domain push initiated on confirmation of funded escrow, repository transferred to the buyer's GitHub organization, Cloudflare Pages reassigned (or migrated to Netlify/Vercel — both are documented drop-in alternatives), one walkthrough call covering operator-grade questions, and a 30-day window of asynchronous support for clarifying questions inside the Escrow.com record. We do not provide ongoing services after that window; the codebase is documented so it does not need us.
The MONETIZATION_PLAYBOOK in the repo specifies the activation order: newsletter first (owned audience), affiliate next (small early revenue, scales with traffic), advertising once traffic crosses ad-network thresholds (typically 50–100k monthly sessions), and lead-gen last (the highest-revenue rail, which needs both audience and partner relationships). A serious operator can usually get rails 1 and 2 live within two weeks of takeover.
The list price reflects a deliberate discount to replacement cost and to comparable content-site transactions (see the valuation breakdown above). The site is sold at list price via Escrow.com — the price is firm. There is no broker, no negotiation step, and no urgency to sell; the listing closes when a buyer funds the Escrow.com checkout.
Anyone planning to flip the editorial stance toward gray-market content, anyone unwilling to maintain medical review on clinical pages, or anyone looking for a turnkey cash-flow business at a starter-site price. The site is a platform for an operator with category context — not a passive-income asset.
Use the "Buy now via Escrow.com" button anywhere on this page to acquire the domain and full website at list price through Escrow.com — the neutral, regulated payments escrow service used for high-value domain and website transactions. Escrow.com holds your funds, verifies the domain transfer to your registrar of choice and the repository handover to your GitHub organization, and only releases funds once you confirm receipt. There is no negotiation step and no broker: the listing is single-buyer, first cleanly executed close.
Buy now
$24,500 USD · list
Acquire the drugtest.co domain and full website at list price through Escrow.com — the neutral, regulated payments escrow service used for premium domain and website transactions worldwide. Escrow.com holds your funds in a regulated trust account while we transfer the domain to your registrar of choice and hand off the repository to your GitHub organization. Funds are released only after you confirm everything is in your control. The full transaction typically completes inside 5–10 business days.
Single buyer. No agency, no broker. Asset is sold as-is unless otherwise agreed. Listing may be withdrawn at any time without notice. Contact the seller with diligence questions before purchase.